Lensar Laser System secured 510(k) clearance from the US Food and Drug Administration (FDA) to perform corneal pockets and flaps for corneal inlay procedures.
Lensar says that the new Laser System can support surgeons by offering the latest presbyopic inlay devices to patients struggling with the loss of near vision with age.
The presbyopia procedure in the Lensar Laser System with Streamline IV includes a new curved contact patient interface device that enables creating corneal pockets and flaps without compromising patient comfort.
Lensar CEO Nicholas Curtis said: “The continued expansion of capabilities with the Lensar Laser System is the latest demonstration of our commitment to technological innovation that serves surgeons pursuing excellent visual outcomes for their patients.
“Lensar’s technology is known for its adaptability and high-quality treatment capability. It made sense to evolve our platform to support surgeons meeting the increasing patient demand with options for the treatment of presbyopia with corneal inlay devices.”
Lensar plans to roll out the new presbyopia procedure capabilities to its users in the US this year. The company has also applied for regulatory approval in the EU and expects the new features to be available later this year, pending approval.
Parkhurst NuVision Gregory Parkhurst said: “This latest innovation from Lensar speaks to the company’s strong partnership with its customers. Adapting the Lensar platform for stromal pockets and corneal flaps delivers on their promise to expand the platform capabilities to facilitate presbyopia inlay procedures.
“Lensar has always been open to feedback from its customer base and this clearance is just the latest example of their ability to incorporate the clinical experience with the technology to drive innovation.”
Image: LENSAR’s Laser System. Photo: Courtesy of Business Wire.